Cannara Biotech Launches Cannabis Vapes in Quebec

The Canadian cannabis producer Cannara Biotech Inc. has announced the launch of five new cannabis-based vaping devices, following receipt of a pre-market authorization from Santé Cannabis Québec. This move comes amid continued growth for the company, which reported record financial results in Q3 2025. Although Cannara Biotech has no ties to the tobacco industry, the announcement underscores the growing convergence between the cannabis, nicotine, and vaping sectors—markets into which tobacco giants are increasingly investing.

Cannara Biotech Diversifies Into Cannabis Vaping

With its announcement of five new cannabis-based vaping products, Cannara Biotech Inc. marks another step in its diversification strategy. Already well-established in Quebec’s recreational cannabis market—where it claims the top spot in sales volume—the company now aims to capitalize on the rise of alternative consumption methods, particularly electronic inhalation devices, to broaden its product portfolio.

These new Cannara Biotech devices, marketed under the “Tribal” brand, are described as technologically advanced, powerful, and designed to offer a cleaner and more discreet user experience. According to company press releases, the vapes will be available starting November 2025, following approval by the provincial regulator responsible for cannabis distribution.

This Cannara Biotech move aligns with a structural trend in the North American cannabis market: the growing popularity of processed, higher-value-added products, particularly smokeless inhalables such as THC cartridges, vape pens (single-use devices for CBD or cannabis), and refillable pods. In 2024, according to a BDSA Analytics study, vape products already made up more than 20% of the Canadian recreational cannabis market, growing at twice the rate of dried flower.

This diversification enables companies like Cannara Biotech to:

• Expand their consumer base, especially among young adults;
• Offer products perceived as more discreet and “modern” than smoked cannabis, facilitating public use;
• Position themselves in the premium segment, with higher margins than traditional flower.

It also brings a wave of technological deployment inspired by nicotine vaping innovations: rechargeable batteries, controlled-dosage systems, specialized flavoring, and mobile app compatibility. This technological overlap blurs the lines between products and encourages crossover consumption—especially in environments where recreational use is increasingly normalized.

At the same time, the proliferation of electronic cannabis products raises new concerns for public health and regulation. While vaping cannabis is often seen as a “safer” alternative to smoking, studies on the specific risks of these devices remain limited—particularly regarding solvents, flavor additives, and high-concentration THC formulations. The combination of these substances with youth-targeted, tech-savvy marketing is a growing concern for prevention advocates.

Blurring Boundaries With Tobacco Products

Although Cannara Biotech is currently neither owned nor funded by the tobacco industry, its entry into cannabis vaping fits into a broader shift that is eroding the boundaries between the tobacco, cannabis, and nicotine industries. The development of similar electronic devices—both in technical and marketing terms—has accelerated this convergence, further fueled by growing investment from tobacco companies in the cannabis sector.

For several years now, companies besides Cannara Biotech, like British American Tobacco (BAT), Philip Morris International (PMI), and Altria, have ramped up activity in cannabis through various strategies: acquisitions of cannabis startups, R&D partnerships, hybrid device development, and financing of cannabis biotech ventures. In 2023, BAT announced an investment in AJNA BioSciences, a U.S. company focused on medical cannabis, in partnership with Canadian producer Organigram, in which BAT already holds a partial stake. This deal is part of a broader effort by BAT to diversify revenue beyond tobacco and nicotine and to position itself as a provider of “reduced-risk alternatives”—a narrative widely challenged by public health authorities.

Meanwhile, PMI is actively exploring the synthetic cannabinoid market, with projects aimed at incorporating cannabis-derived substances into its electronic devices. In parallel, several former executives from major tobacco multinationals have joined the boards of cannabis companies or invested privately in THC or CBD vaping ventures.

This strategy of convergence raises serious public health concerns. On one hand, it normalizes psychoactive substance products by marketing them as modern, tech-forward, or “better controlled.” On the other, it creates regulatory confusion: while tobacco and nicotine are increasingly tightly regulated, the still-developing cannabis sector is becoming a prime target for corporations seeking new markets—especially among youth, already heavily exposed to industry messaging on social media.

The case of Cannara Biotech illustrates a gradual migration of business models and marketing strategies from tobacco into cannabis, with increasingly addictive, standardized products embedded in cross-promotional ecosystems. While Cannara itself is not affiliated with any tobacco firm, the launch of its vape lineup offers a textbook example of this evolving dynamic.

__

(Featured image by Chiara Summer via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Generation Sans Tabac. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.